AFFILIATED EYE SURGEONS | CORNEAL CARE
Corneal Cross-Linking (CXL) for Keratoconus in Northern New Jersey
The only FDA-approved treatment proven to halt
keratoconus progression — performed by a
specialized corneal team at
three convenient locations in Morris and Essex counties.
Stop Keratoconus in Its Tracks
For patients with progressive keratoconus, corneal cross-linking (CXL) is a pivotal intervention — the only FDA-approved treatment that can stop the cornea from continuing to thin and distort. Left untreated, progressive keratoconus can advance to the point where even specialty contact lenses can no longer restore functional vision, and corneal transplantation becomes necessary. Cross-linking changes that trajectory.
At
Affiliated Eye Surgeons, our corneal specialist
Dr. Sanjai Jalaj has extensive experience performing corneal cross-linking for keratoconus and other forms of corneal ectasia. If you have been diagnosed with keratoconus and have documented progression — or if you suspect your condition may be worsening — a cross-linking evaluation is an important and potentially vision-preserving step.
What Is Corneal Cross-Linking?
Corneal cross-linking (CXL) is a minimally invasive outpatient procedure that uses riboflavin (vitamin B2) eye drops combined with a controlled dose of ultraviolet-A (UV-A) light to create new collagen cross-links within the cornea's inner structural layer (the stroma). These new bonds dramatically increase the cornea's mechanical stiffness and resistance to further distortion — halting or significantly slowing the progression of keratoconus.
The concept draws on well-established photochemistry: riboflavin acts as a photosensitizer, and when activated by UV-A light, it catalyzes the formation of covalent bonds between the collagen fibers of the corneal stroma. The result is a structurally stronger cornea — one that is far less likely to continue thinning and bulging under the biomechanical stresses that drive keratoconus progression.
Who Needs Corneal Cross-Linking?
Not every
keratoconus patient needs corneal cross-linking — and not every patient is a candidate. The procedure is indicated when there is evidence of active progression, meaning the corneal shape or thickness has measurably changed over time. This is why regular monitoring with corneal topography is so important for every keratoconus patient.
You may be a candidate for corneal cross-linking if you:
- Have documented keratoconus progression on serial corneal topography or tomography
- Are under 40 years old — younger patients are at greatest risk of progression
- Have keratoconus that has not yet reached the advanced stage (cornea must have sufficient thickness)
- Have not developed significant corneal scarring that would require transplantation regardless
- Are motivated to preserve your current vision and reduce the risk of future surgical intervention
Cross-linking may not be appropriate if you:
- Have a cornea that is too thin to safely undergo the procedure (generally below 400 microns after epithelial removal)
- Have significant corneal scarring that would make transplantation necessary regardless of cross-linking
- Have keratoconus that has already stabilized naturally with no documented progression
- Have active eye infections or certain ocular surface conditions that need to be treated first
The Corneal Cross-Linking Procedure, Step by Step
Corneal cross-linking is an outpatient procedure performed in our office under topical anesthesia. The procedure takes approximately 60 to 90 minutes per eye. Here is what to expect:
1. Pre-Operative Preparation
Numbing eye drops are applied. The eye is cleaned and prepped. A lid speculum gently holds the eye open throughout the procedure.
2. Epithelial Removal (epi-off CXL)
The thin outer layer of the cornea (epithelium) is gently removed using a blunt instrument or dilute alcohol solution. This is the standard technique that allows deep riboflavin penetration into the corneal stroma.
3. Riboflavin Application
Riboflavin (vitamin B2) eye drops are applied to the cornea every 2 minutes for approximately 30 minutes, saturating the corneal stroma. The riboflavin solution is specifically formulated to achieve optimal stromal concentration.
4. UV-A Light Exposure
A calibrated UV-A light source is positioned over the eye and delivers a precise, controlled dose of ultraviolet-A light for approximately 30 minutes. The riboflavin absorbs the UV-A energy and triggers the photochemical reaction that forms new collagen cross-links.
5. Bandage Contact Lens Placement
At the end of the procedure, a soft bandage contact lens is placed on the eye to protect the healing corneal surface and improve comfort during the epithelial recovery period.
6. Recovery Begins
The eye will be uncomfortable, light-sensitive, and vision will be blurry for the first several days while the epithelium regenerates. The bandage lens is removed at a follow-up visit 3 to 5 days later once the surface has healed.
Epi-Off vs. Epi-On Cross-Linking: What's the Difference?
There are two main CXL techniques — distinguished by whether or not the corneal epithelium is removed before riboflavin application.
Your surgeon will recommend the most appropriate approach based on your individual anatomy and disease severity.
Epithelium-Off (Epi-Off) CXL — The FDA-Approved Standard
Epithelium-On (Epi-On / Transepithelial) CXL
In epi-off CXL, the epithelium is removed before riboflavin drops are applied. This allows riboflavin to penetrate deeply into the corneal stroma, enabling more effective cross-linking at greater depth. Epi-off CXL has the most robust long-term clinical evidence — it is the technique used in the pivotal FDA approval trials and is widely regarded as the gold standard for halting keratoconus progression.
The trade-off is a more uncomfortable recovery: the eye is essentially an open wound for 3 to 5 days until the epithelium grows back. Most patients manage this with prescribed medications and rest.
In epi-on CXL, the epithelium is left intact and a modified riboflavin formulation with permeability enhancers is used to allow some penetration through the surface. Recovery is significantly more comfortable — vision returns faster and there is no open corneal surface. However, riboflavin penetration is reduced compared to epi-off, and long-term efficacy data is less established.
Epi-on CXL is not FDA-approved in the same manner as epi-off. It may be offered in certain clinical contexts but is not the standard first-line approach for most progressive keratoconus patients. Your surgeon will discuss which technique is most appropriate for your case.
What to Expect After Corneal Cross-Linking
Cataract surgery recovery is generally quick and comfortable. Here's what most patients experience:
Day 1-5
Significant discomfort, light sensitivity, tearing, and blurry vision while the corneal epithelium regenerates. The bandage contact lens helps protect the surface. Prescription pain medication and antibiotic/anti-inflammatory drops are used during this period. Most patients take several days off from work or school.
Day 3-5
A follow-up visit is scheduled to remove the bandage contact lens once the epithelium has healed. Vision begins to improve noticeably after this point.
Weeks 1-4
Vision gradually returns to the pre-procedure level. Some patients experience temporary fluctuation or mild regression before stabilization. Anti-inflammatory drops continue.
Months 1-6
Serial corneal topography is performed at 1 month, 3 months, and 6 months to assess corneal stabilization and confirm that progression has halted.
6-12 Months and Beyond
Most patients demonstrate stabilization within 6 months. Annual corneal topography continues for long-term monitoring. Some patients notice modest improvement in corneal regularity over the first 1-2 years as the cornea settles.
Contact Lenses
Specialty contact lenses (scleral or RGP) can typically be refitted 4 to 6 weeks after the procedure once the cornea has fully healed. A refit may be needed if the corneal shape has changed.
Why Choose Affiliated Eye Surgeons for Corneal Cross-Linking?
Specialized Corneal Expertise — Sajai Jalaj, MD
Corneal cross-linking is a specialized procedure that requires precise technique, meticulous patient selection, and ongoing experience with the nuances of corneal ectatic disease.
Dr. Sanjai Jalaj brings fellowship-trained corneal expertise to every CXL procedure, with deep experience in managing keratoconus from initial diagnosis through cross-linking,
specialty lens fitting, and — when necessary — surgical intervention. This is not a procedure we offer as an add-on; it is a core part of our corneal subspecialty practice.
Comprehensive Pre-Procedure Evaluation
We do not perform cross-linking without thorough pre-operative evaluation. Every CXL candidate undergoes serial corneal topography and tomography to confirm documented progression, measure corneal thickness, and stage the severity of disease. This ensures that cross-linking is genuinely indicated — and that the cornea is safe to treat.
Meticulous Post-Procedure Monitoring
The work doesn't end when the procedure is over. Long-term outcomes in keratoconus depend heavily on consistent follow-up corneal imaging to confirm stabilization. Our practice provides structured post-CXL monitoring — topography at defined intervals, medication management, and contact lens refitting — all within the same practice where your keratoconus is managed.
Integrated Keratoconus Care
Corneal cross-linking is most effective as part of a comprehensive keratoconus management plan — not as a standalone procedure. At Affiliated Eye Surgeons, your cross-linking is integrated with your contact lens care, your corneal monitoring, and — if ever needed — your surgical planning. Everything is coordinated within one specialized practice.
Three Convenient Northern New Jersey Locations
Cross-linking evaluations and follow-up care are available at our offices in
Morristown,
West Orange, and
Denville — making it easy to stay consistent with the monitoring that keratoconus management requires.
Frequently Asked Questions
What is corneal cross-linking?
Corneal cross-linking (CXL) is an FDA-approved minimally invasive procedure that uses riboflavin (vitamin B2) eye drops combined with controlled ultraviolet-A light to create new collagen bonds within the cornea, strengthening and stiffening it. It is the only proven treatment to stop the progression of keratoconus. The procedure takes approximately 60 to 90 minutes per eye and is performed on an outpatient basis under topical anesthesia.
Does corneal cross-linking improve vision?
Corneal cross-linking is designed to stop progression, not to improve vision directly. Most patients maintain the vision they had before the procedure. Some patients experience modest improvement in corneal shape over the months following CXL as the cornea stabilizes, which may slightly improve contact lens fitting or visual acuity. However, patients should not expect CXL alone to significantly sharpen their vision — specialty contact lenses remain the primary tool for vision correction in keratoconus.
How do I know if I need corneal cross-linking?
The primary indication for corneal cross-linking is documented progression — measurable change in corneal shape or thickness on serial corneal topography or tomography over time. Your surgeon will compare maps taken at different intervals to identify signs of change. If you have not had serial corneal topography, an evaluation at Affiliated Eye Surgeons is the first step. CXL is most beneficial for younger patients in their teens and 20s whose disease is more likely to progress.
Is corneal cross-linking painful?
The procedure itself is performed with numbing eye drops and is not painful. The recovery period — the first 3 to 5 days while the corneal epithelium heals — can involve significant discomfort, light sensitivity, tearing, and blurred vision. Most patients manage this with prescribed pain medication and rest. A bandage contact lens placed at the end of the procedure helps protect the eye and improve comfort during healing.
What is the difference between epithelium-off and epithelium-on cross-linking?
In standard epithelium-off (epi-off) CXL, the thin outer corneal layer (epithelium) is removed before riboflavin is applied, allowing deeper penetration and more effective cross-linking. It is the FDA-approved standard with the most long-term clinical evidence. Epithelium-on (epi-on) CXL leaves the epithelium intact for a more comfortable recovery, but riboflavin penetration is reduced and long-term efficacy data is less established. Your surgeon will recommend the appropriate technique based on your corneal thickness, disease severity, and other individual factors.
How long does corneal cross-linking take?
The corneal cross-linking procedure takes approximately 60 to 90 minutes per eye, including preparation, riboflavin application time, and UV-A light treatment. You should plan to be at the facility for approximately 2 to 3 hours total. The procedure is performed on one eye at a time, with the second eye scheduled at a separate visit typically 2 to 4 weeks later.
How long does it take to recover from corneal cross-linking?
The initial recovery — epithelial healing — takes approximately 3 to 5 days, during which the eye will be uncomfortable and vision blurry. Most patients take several days off from work or school. Vision typically returns to its pre-procedure level within 1 to 4 weeks. Full corneal stabilization — the true measure of success — is assessed over 6 to 12 months through serial corneal topography.
Can I still wear contact lenses after cross-linking?
Yes. After the cornea has fully healed — typically 4 to 6 weeks after the procedure — patients can resume wearing their specialty contact lenses. In some cases the corneal shape changes slightly after CXL as the cornea stabilizes, which may require a refit of scleral or RGP lenses. Your contact lens fitting appointment will be scheduled at the appropriate time in your follow-up care plan.
Is cross-linking covered by insurance?
Coverage for corneal cross-linking varies by insurance plan. Since receiving FDA approval in 2016, many major insurance carriers and Medicare Advantage plans have begun covering CXL for progressive keratoconus when medical necessity criteria are met — which typically requires documentation of progression on serial corneal topography. Our team will verify your individual coverage before the procedure and provide a clear explanation of any out-of-pocket costs.
Will cross-linking prevent me from needing a corneal transplant?
Corneal cross-linking significantly reduces the likelihood of needing a corneal transplant by halting the progression that would otherwise lead to advanced corneal distortion. Studies show CXL reduces the need for corneal transplantation in progressive keratoconus patients. However, CXL cannot reverse scarring or distortion that has already occurred. For patients with already-advanced keratoconus, transplantation may still be necessary. This is why early diagnosis and early treatment — before the cornea has become severely distorted — produce the best outcomes.
